We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva Strikes $24M Deal To Exit Nexium Pay-For-Delay Suit

Law360, San Diego (April 2, 2015, 10:47 PM EDT) -- Class action plaintiffs in a pay-for-delay case over generic versions of AstraZeneca PLC’s heartburn drug Nexium disclosed on Thursday a $24 million settlement freeing Teva Pharmaceutical Industries Ltd. from the case, according to filings in Massachusetts federal court.

The plaintiffs said Teva had reached a joint arrangement with direct and indirect purchasers as well as individual plaintiffs, with the money being used to reimburse them for past costs and expenses tied to the multidistrict litigation.

The plaintiffs claim that AstraZeneca essentially paid off Teva to keep the company from bringing a generic version of the heartburn treatment to market and that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS